Bispecific Antibody Active in Heavily Treated Multiple Myeloma

(MedPage Today) -- Almost 60% of patients with heavily pretreated multiple myeloma responded to an investigational bispecific antibody, results from an ongoing phase I trial showed.
Overall, 57% of 124 patients had at least partial response to...